key: cord-0831321-v3xdjsam
authors: Akther, Lutfa; Shahnewaz, Shaila Sharmin; Ferdous, Dilruba; Pramanik, Md. Moyen Uddin
title: Diagnosis, management, and recovery from COVID‐19: A case report from bangladesh
date: 2021-02-11
journal: Clin Case Rep
DOI: 10.1002/ccr3.3895
sha: ea1a5558542a1cb0e2414d20d170518e8c1631be
doc_id: 831321
cord_uid: v3xdjsam

There is no known medicine for COVID‐19, and thus, the clinical management is symptomatic. More than 80% people experience mild symptoms who can be treated at home for fever, sore throat, and cough. About 15% patients develop severe illness require O2.

A 30-year-old man with no travel history to COVID-19prone areas had the characteristic signs and symptoms of COVID-19. Chest X-ray and RT-PCR confirmed his COVID-19 diagnosis. This study recommends the early identification and management of COVID-19.

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China, in December 2019. 1 The World Health Organization (WHO) declared a public health emergency of international concern regarding this global outbreak on 30 January 2020. Globally, there have been 5 796 257 confirmed cases and 362 483 deaths from COVID-19 reported to the WHO as of 9:37 AM CEST on 30 May 2020. 2 In Bangladesh, there have been approximately 52 000 confirmed cases of COVID-19 with about 700 deaths as of 4 June 2020. The SARS-CoV-2 virus is primarily transmitted between humans through respiratory droplets and contact routes. Analysis of 75 465 COVID-19 cases in China failed to detect airborne transmission. [3] [4] [5] Early disease symptoms offer an opportunity for early detection. 6, 7 Fast identification and accurate treatment have been critical to prevent the spread of infection. 8, 9 At present, reverse transcription polymerase chain reaction (RT-PCR) and real-time RT-PCR (qRT-PCR) are used to detect SARS-CoV-2. There are three genes expressed by SARS-CoV-2, including the RNA-dependent RNA polymerase (RdRp)/helicase (Hel), spike (S), and nucleocapsid (N) genes 10, 11 In Bangladesh, qRT-PCR is used to detect early COVID-19. After a week, point-of-care test kits for antigen and antibodies are used to measure the protective | 1749

level of plasma IgM and IgG antibodies. In this study, we reported a case of COVID-19 in a man with no travel history to COVID-19-prone areas, yet he had the characteristic signs and symptoms of COVID-19. Chest X-ray and qRT-PCR confirmed his COVID-19 diagnosis.

On 13 April 2020 at 11:30 AM, a 30-year-old man presented to a tertiary hospital in Dhaka, Bangladesh, with the signs and symptoms of COVID-19. He had dry cough, muscle pain, fever, headache, and shortness of breath. He was immediately admitted and recorded the vital signs of COVID-19, which are shown in Table 1 . He had no history of direct contact with any COVID-19-positive individuals. On 14 April at 10:15 PM, his COVID-19 diagnosis was confirmed using an RT-PCR nasal swab test (Table 2 ). At 12:45 AM, he was moved to an isolated cabin and received supportive treatment. On 15 April at 9:45 PM, we received his complete blood count results, which did not identify leukocytopenia. Chest X-ray, on the other hand, showed ground-glass opacities in the center and lower right portion of his lung (Table 2 ). This finding strongly indicated COVID-19. On 16 April at 10:30 AM, new nasal and throat swabs were tested for SARS-CoV-2 by RT-PCR, and the findings were positive. At 11:35 PM, he was treated with antibiotics (azithromycin, 500 mg), O 2 inhalation, intravenous fluids, acetaminophen (500 mg), montelukast (10 mg), and fexofenadine (120 mg). After 3 days of treatment (19 April 2020), his fever and breathing improved, and his condition was stable for 72 hours. On 23 and 24 April, he was retested for SARS-CoV-2 RNA with two independent throat swabs; both were negative ( Table 2) . On 25 April at 11:25 AM, he was discharged and recommended to follow the requirements to home quarantine for the next 14 days. During his 1 May 2020 follow-up, it was recommended that he monitors his blood IgM and IgG against SARS-CoV-2. Antibodies (IgM and IgG) were measured using a point-of-care test, which detected a protective level of IgG ( Table 2 ). The snapshot of COVID-19 is shown in Figure 1 .

Severe COVID-19 illness begins after approximately 7 days after symptom onset. The most common symptoms of COVID-19 are fever, cough, tiredness, dyspnea, and diarrhea. 12, 13 Severe COVID-19 dyspnea triggers progressive respiratory failure followed by severe hypoxemia. In addition, lymphopenia is a frequent symptom of severe COVID-19. 14,15 COVID-19 is diagnosed and monitored using qRT-PCR, partial or complete viral genome sequencing, and plasma antibody-level measurements. Early SARS-CoV-2 is detected by collecting, processing, and analyzing respiratory samples, such as nasopharyngeal aspirates, combined (nasal and oral) swab samples, sputum, tracheal lavage fluid, or bronchoalveolar lavage fluid. 16 RNA is isolated from respiratory samples and measured utilizing qRT-PCR with SARS-CoV-2-specific primers. 17 Within a week of COVID-19-symptom onset, plasma IgM and IgG tests easily detect the infection. It showed that a patient had the protective amount of IgG within 14 days. Point-of-care tests can identify serum antibodies in 15 minutes and can determine the level of the infection. 18 proven successful treatment for COVID-19. Antiviral medications and respiratory treatment are the primary approaches used to cure the disease. In addition, while several therapies have been suggested, quarantine is the only method that seems to be successful.

The most critical aspect of treatment in this case study was close observation of the patient's respiratory condition to assess whether a ventilator was necessary. The patient was recommended to quarantine at home for 2 weeks (14 days) with proper food management. This 2-week period provides adequate time to determine whether or not they have been infected and are able to spread the infection to other citizens.

The patient provided informed consent for the release of this case study. Published with written consent of the patient.

A Review of Coronavirus Disease-2019 (COVID-19)

WHO.WHO Coronavirus Disease (COVID-19) Dashboard 2020

Community transmission of severe acute respiratory syndrome coronavirus 2

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Active monitoring of persons exposed to patients with confirmed COVID-19 -United States

Current overview on hypercoagulability in COVID-19

An atypical presentation of novel coronavirus disease 2019 (COVID-19)

COVID-19: what has been learned and to be learned about the novel coronavirus disease

The epidemiology, diagnosis and treatment of COVID-19

Real-time sequence-validated loop-mediated isothermal amplification assays for detection of middle east respiratory syndrome coronavirus (MERS-CoV)

Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Acute respiratory distress syndrome: the Berlin Definition

Information about the new coronavirus disease (COVID-19). Radiol Bras

Understanding antibody testing for COVID-19

Diagnosing COVID-19: the disease and tools for detection

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The authors declare that there are no conflicts of interest.

Lutfa Akther, Shaila Sharmin Shahnewaz, and Dilruba Ferdous: were involved in data collection and reviewed the manuscript. Md. Moyen Uddin Pramanik: analyzed the data and wrote the manuscript.

This case study does not include any scientific trials involving human subjects. 

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Md. Moyen Uddin Pramanik https://orcid. org/0000-0001-9026-8518